Previous 10 | Next 10 |
Multiple AACR Presentations Highlight Potential Advantages of RAS(ON) Inhibitors; Scientific Publication is First to Demonstrate Anti-Drug Resistance Features Continued Advancement and Enrollment of Multiple RMC-4630 RAS Companion Inhibitor Combination Studies; Initiated Cli...
REDWOOD CITY, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today highlights the nomination of a slate of three ind...
This year, Revolution Medicines (RVMD) does not anticipate clinical data from Phase 1b study of RMC-4630/AMG 510 (sotorasib) combination in patients with advanced solid tumors with the KRASG12C mutation.AMG 510 is a KRASG12C(OFF) inhibitor and RMC-4630, a RAS Companion Inhibitor, is...
Gainers: Brooklyn ImmunoTherapeutics (BTX) +44%.Uxin (UXIN) +25%.Ashford Hospitality Trust (AHT) +24%.Boxlight (BOXL) +21%.ADMA Biologics (ADMA) +18%.Clover Health Investments (CLOV) +16%.Unitil (UTL) +15%.Pitney Bowes (PBI) +15%.ClearSign Technologies (CLIR) +15%.Microvision (MVIS) ...
Gainers: ADMA Biologics (ADMA) +25%, Brooklyn ImmunoTherapeutics (BTX) +23%, Clover Health Investments (CLOV) +15%, Neptune Wellness Solutions (NEPT) +12%, Akouos (AKUS) +11%.Losers: Protalix BioTherapeutics (PLX) -40%, Benitec Bioph...
Revolution Medicines (RVMD) has dosed the first patient in a multicenter Phase 1/1b clinical trial evaluating RMC-5552, an investigational bi-steric mTORC1 inhibitor as a monotherapy.The trial is designed to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics of RMC-5...
First-in-Class Bi-steric mTORC1 Inhibitor Advances into Clinical Development Newly Issued U.S. Patent Further Strengthens RMC-5552 IP Portfolio REDWOOD CITY, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision on...
The notoriously difficult-to-target RAS cancer mutations may soon have a new enemy, and 230,000 U.S. cancer patients with RAS mutations may soon have good news. Revolution Medicines (NASDAQ: RVMD) and its lead compound, RMC-4630, are looking to become the backbone of treatment f...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The energy and shipping markets take center stage next week as the drama in the Suez Canal continues to play out and OPE...
The following slide deck was published by Revolution Medicines, Inc. in conjunction with this event. For further details see: Revolution Medicines (RVMD) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Revolution Medicines Inc. Company Name:
RVMD Stock Symbol:
NASDAQ Market:
Revolution Medicines Inc. Website:
2024-07-24 09:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-14 06:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) Re...